ANI Pharma buys 31 generic drugs from Teva

27 December 2013
mergers-acquisitions-big

Emerging US generic drugmaker ANI Pharmaceuticals (Nasdaq: ANIP) says that it has acquired 31 previously marketed generic drug products from Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA).

Under the terms of the deal, Teva will receive $12.5 million in cash and a percentage of future gross profits from product sales. ANI's shares rose 5.1% to $18 in after hours trading on December 26.

The acquisition includes 20 solid-oral immediate release products, four extended release products and seven liquid products. ANI will begin work immediately on transferring these products into its manufacturing facilities in anticipation of product launches beginning in the fourth quarter of 2014.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics